NCT04940286View on ClinicalTrials.gov

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions
Borderline Resectable Pancreatic AdenocarcinomaResectable Pancreatic AdenocarcinomaStage IA Pancreatic Cancer AJCC v8Stage IB Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8
Interventions
BIOLOGICAL

Durvalumab

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Nab-paclitaxel

Given IV

BIOLOGICAL

Oleclumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER